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Abstract
Background: The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155)
antibodies.
Methods: Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-
control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only
studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were
performed to analyze overlap between presented peptides and antigenic regions.
Results: DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in
only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in
significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57.
30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p =
0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR
= 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the
peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology.
Conclusions: DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence
that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.
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Background
Chronic inflammatory demyelinating polyradiculoneuro-
pathy (CIDP) is a heterogeneous autoimmune disease af-
fecting peripheral nerves. Diagnosis relies on clinical and
electrophysiological criteria built to identify patients that
may respond to immunomodulatory treatments [1]. The
recent description of antibodies targeting proteins at node
of Ranvier, such as contactin-1 (CNTN1) [2], neurofascin-
155 (NF155) [3], contactin-associated protein 1 (CASPR1)
[4], and nodal neurofascins [5], has revealed the existence
of CIDP subsets with clinical features that associate specif-
ically to each antibody. In the case of anti-NF155, patients
show predominantly distal weakness, ataxia, and a low
frequency tremor [3]. They respond to intravenous immu-
noglobulins (IVIg) less frequently than anti-NF155neg
CIDP [6], and when resistant to conventional treatment,
they may respond well to B cell depleting therapies [7].
Anti-NF155 antibodies are predominantly IgG4, an isotype
unable to fix complement or activate inflammatory cells
[6]. Interestingly, anti-NF155 CIDP patients show distinct
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pathological features that differ from those of typical
CIDP patients, including lack of macrophage infiltrates
and a selective loss of the transverse bands at the
paranodal loops [8, 9]. Thus, the clinical, pathological,
and electrophysiological diversity of CIDP disappears
when patients are sub-classified according to specific
autoantibodies.
There is no epidemiological, environmental, or genetic
evidence that explains the appearance of anti-NF155
antibodies, and evidence for the existence of CIDP-specific
risk factors is lacking, including genetic association studies.
Human leukocyte antigen (HLA) loci are the group of
genetic factors that has most frequently been associated
with autoimmune diseases, including strong associations
with other IgG4-mediated diseases [10–12]. Moreover,
association of HLA genes with specific antigens can help
discover the specific peptide sequence driving the immune
response [10]. Considering the association of other IgG4-
mediated diseases to HLA class II, we aimed our study to
identify specific HLA class II alleles associated to anti-
NF155 antibodies in CIDP.
Methods
Patients, samples, protocol approvals, and patient
consents
Patients fulfilling EFNS/PNS diagnostic criteria for CIDP
that were positive for anti-NF155 antibodies were included
[13]. CIDP patients without detectable anti-NF155 or anti-
contactin-1 autoantibodies (anti-NF155neg CIDP) were
used as controls. Serum and DNA samples were obtained
from CIDP patients, processed and frozen until needed.
Anti-NF155 antibody detection and isotype analysis
Antibodies against NF155 were detected by immunocyto-
chemistry over human NF155 transfected-HEK293, and
ELISA was used for autoantibody isotype identification as
previously described [3].
HLA genotyping
Genomic DNA from the peripheral blood of 13 anti-
NF155+ CIDP patients, and 35 CIDP patients without
anti-NF155 antibodies (anti-NF155neg CIDP) was ex-
tracted following standard protocols. HLA-DRB1 and
HLA-DQB1 genotypes were determined at the four-digit
allele levels using DNA sequence analysis following manu-
facturers’ instructions for HLA-DRB1 (SBT Excellerator
GenDx HLA-DRB1, GenDx, Utrecht, Netherlands) and
SSP methodology for HLA-DQB1 (All Set Gold SSP, One
Lambda, California, USA). HLA-DRB1*15 allele frequen-
cies were calculated for anti-NF155+ CIDP and compared
with their frequency in anti-NF155neg CIDP patients and
normal Spanish population (Spain-Barcelona, 941 controls
included) previously published and available at public
databases (allefrequencies.net) [14].
In silico HLA-peptide binding and NF155 antigenicity
predictions
In silico assays to predict NF155 binding to specific DRB1
alleles were developed using the IEDB analysis resource
consensus [15, 16] and ProPred [17] tools during April and
May 2017. The human NF155 sequence (NP_001153803.1)
was used to predict peptides binding with higher affinity to
those HLA alleles associated with anti-NF155+ antibodies.
Peptides that were predicted to bind to both DRB1*15:01
and DRB1*15:02 alleles were considered.
Additionally, the Kolaskar and Tongaonkar antigenicity
scale was used to predict NF155 antigenic targets. This
scale values physicochemical properties of amino acid
residues and their frequencies to predict antigenic deter-
minants on proteins [18]. Predicted antigenic targets were
compared with the results of the HLA-peptide binding
prediction analysis in search of overlap.
Statistical analyses
Data were collected in a coded database. Fisher’s exact
test, odds ratio, and confidence interval calculations
were performed using the GraphPad Prism v5.0 package.
Results
Association of anti-NF155 antibodies with DRB1*15
Thirteen CIDP patients with anti-NF155 IgG4 antibodies
and 35 anti-NF155neg CIDP patients were included in the
study. In all anti-NF155+ patients, antibodies were predom-
inantly of the IgG4 isotype. As previously described [6]
anti-NF155+ patients were younger than anti-NF155neg
CIDP (47 vs 61; p = 0.03, Mann-Whitney), but there were
no differences in gender or ethnicity. Demographic features
are detailed in Table 1.
DRB1*15 alleles were present in 10 out of 13 anti-NF155
+ CIDP patients and in only 5 out of 35 anti-NF155neg
CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13).
Proportion of DRB1*15 alleles was also significantly higher
in anti-NF155+ CIDP than in normal population (77 vs
17%; OR = 16.9, CI = 4.434 to 57.30) (Fig 1a). Seven (53%)
anti-NF155+ CIDP patients, 5 (14%) anti-NF155neg CIDP
patients (OR = 7, CI = 1.651 to 29.68), and 132 (14%)
controls had the DRB1*15:01 allele (OR = 7.15, CI = 2.366
to 21.61) (Fig 1b). Finally, three (23%) anti-NF155+ CIDP
patients, none (0%) of the anti-NF155neg CIDP patients
(OR = 23.6, CI = 1.129 to 496.2), and 23 (2%) controls (OR
= 11.97, CI = 3.088 to 46.43) had the DRB1*15:02 allele
(Fig 1c). HLA results are detailed in Table 2.
DQB1*6 alleles strongly associate with DRB1*15 alleles
due to linkage disequilibrium. In our cohort, of those
patients with DRB1*15 alleles, DQB1*6 was found in 8
anti-NF155+ CIDP patients and in all anti-NF155neg
CIDP (80 vs 100%, non-significant) suggesting that the
drivers of the association are the DRB1*15 alleles.
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No other HLA class II allele was associated with anti-
NF155 antibodies in CIDP, and DRB1 frequencies of
anti-NF155neg CIDP patients did not differ to those of
the general population.
Prediction of NF155 peptide binding to DRB1*15
In silico prediction of NF155 peptides binding with
higher scores to DRB1*15 yielded a significant overlap
between the ProPred and IEDB prediction methods
(Additional file 1). Most of the top peptides predicted
for the DRB1*15:01 allele were also predicted for the
DRB1*15:02, probably reflecting the minor differences
between both alleles. Interestingly, one of the top 10
predicted peptides with all methods was also predicted
with the highest antigenicity using the Kolaskar and
Tongaonkar antigenicity scale (Additional file 1).
Discussion
Our study finds a strong association of DRB1*15 alleles
with anti-NF155+ CIDP compared to anti-NF155neg CIDP
and general population. Specifically, anti-NF155+ CIDP pa-
tients have a DRB1*15 allele 20 times more likely than anti-
NF155neg CIDP patients. This finding represents the first
strong association of a CIDP subset with a specific genetic
background and opens a new field =of study to investigate
the interactions of the antigen presenting B cells, the Tcells,
and the immunological environment leading to IgG4 anti-
NF155 antibody production.
Association of specific HLA alleles with autoimmune
diseases is one of the most frequent topics of research in
translational immunology and is used in several diseases
(Behçet disease, ankylosing spondylitis, and others) as a
diagnostic biomarker. Recent studies have found strong
associations of certain HLA alleles in diverse tissue-
specific IgG4-mediated diseases, such as LGI1 encephalitis
(DRB1*07:01–DQB1*02:02 haplotype) [10], anti-MusK
myasthenia (DR14-DQ5 haplotype) [19], or anti-IgLON5
disease (DRB1*10:01-DQB1*05:01) [11]. Early studies in
CIDP did not find any association with specific HLA
alleles, including studies addressing specifically the DRB1
frequencies in chronic autoimmune neuropathies. Other
studies describe a weak association of specific HLA class I
alleles with CIDP in some populations [20]. Considering
that the effector mechanism in anti-NF155+ CIDP is B cell
mediated, we focused in HLA class II associations, instead
of HLA class I. Also, although this study did not aim to
study specifically the association of HLA class II with anti-
NF155neg CIDP, we did not find any difference in class II
allele frequencies compared to general population.
DRB1*15 was not present in three (out of 13) anti-
NF155+ CIDP patients, suggesting that HLA DRB1*15 is a
strong risk factor but probably not a necessary factor for
the development of anti-NF155 antibodies. This agrees
with results in other IgG4-mediated diseases in which the
Table 1 Basic demographic data. CIDP patients with (NF155+
CIDP) or without (anti-NF155neg CIDP) anti-NF155 IgG4
antibodies showed similar gender proportions. They differed in
age, NF155+ CIDP being younger than anti-NF155neg CIDP
NF155+
CIDP
ANTI-NF155neg
CIDP
Gender (male, %) 69% 57% ns
Age (mean) 47 61 p =
0.03*
Ethnicity—Caucasian
(%)
92% 97% ns
ns: non-significant; * Mann-Whitney
Fig. 1 DRB1*15 allele frequencies. DRB1*15 alleles were present in
significantly higher proportion of anti-NF155+ CIDP patients than
anti-NF155neg CIDP or healthy controls, either in combination (a) or
when analyzing DRB1*15:01 (b) and DRB1*15:02 (c) separately
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associated HLA alleles are not universally found in all
patients but with odds ratios ranging 8 to 100 and
frequencies ranging 50 to 90% of patients [10, 19]. The
DRB1 alleles found in those three anti-NF155+ CIDP, but
DRB1*15 negative patients were also present in controls at
similar frequencies; it is unlikely that they influenced their
anti-NF155 antibody development.
The two DRB1*15 alleles found in CIDP patients
(DRB1*15:01 and DRB1*15:02) reach statistical signifi-
cance for their association with anti-NF155 antibodies
independently. However, it is likely that the association
with two different DRB1*15 alleles is not influencing the
underlying peptide presentation process. DRB1*15:01
and DRB1*15:02 only differ in one amino acid (codon
86). Moreover, in silico experiments predicted common
peptides binding to both alleles, suggesting that probably
the same (or a very similar) peptide of NF155 could be
presented with similar efficiency in both DRB1*15 alleles.
A limitation of our study is that, due to the low
frequency of the disease, patients from four different
origins (Spain, France, Italy, and UK) were included,
while the statistical analysis where performed with
Spanish controls. HLA-DRB1*15 is found in 17% of
Spanish population, 12% of North Italy population, 25%
of Southern France population, and 20% of English
population (www.allelefrequencies.net). Considering the
country of origin of the anti-NF155+ CIDP (7 Spain, 3
Italy, 2 France, and 1 England), these differences would
not change the fact that anti-NF155+ CIDP patients
show very high frequencies of DRB1*15 alleles com-
pared to control populations, regardless of the origin of
the control population used as reference.
Interestingly, DRB1*15 is also associated with multifocal
motor neuropathy [21], although anti-NF155 are absent in
this disease [22]; DRB1*15:01 also associates with multiple
sclerosis [23], in which some studies described antibodies
against NF155 associating to specific MS subtypes [24]. In
fact, anti-NF155 antibodies have been described in patients
with combined central and peripheral demyelination, but
these findings have not been replicated in independent
cohorts [25, 26]. None of our patients presented with
symptoms or signs in the neurological exam suggesting
central demyelinating disease. Moreover, 9 out of 13 anti-
Table 2 Detailed HLA class II results including DRB1 alleles from
all patients and DQB1 from DRB1*15 positive patients
CIDP type ID DRB1* DRB1* DQB1* DQB1*
NF155 1.BIR 3:01 4:01 02:– 3:01
NF155 5.ES 1:02 10:01 5:01 5:01
NF155 1.MAR 3:01 13:02 2:01 6:04
NF155 ITA-39 1:02 15:01 05:– 6:02
NF155 3.ES 1:02 15:01 5:01 5:02
NF155 4.ES 1:02 15:01 5:01 6:03
NF155 29.ES 4:04 15:01 3:02 6:02
NF155 19.ES 8:01 15:01 4:02 6:02
NF155 26.ES 11:04 15:01 6:02 6:02
NF155 2.MAR 14:01 15:01 5:01 6:02
NF155 ITA-40 7:01 15:02 02:– 6:01
NF155 23.ES 11:01 15:02 3:01 6:01
NF155 ITA-41 15:02 15:02 05:– 05:–
Negative 2.ES 1:01 1:03
Negative ITA-12 1:01 3:01
Negative ITA-10 1:02 3:01
Negative 10.ES 3:01 3:01
Negative 6.ES 1:03 4:02
Negative ITA-7 3:01 4:06
Negative ITA-18 1:01 7:01
Negative 7.ES 3:01 7:01
Negative 11.ES 3:01 7:01
Negative ITA-16 3:01 8:01
Negative 8.ES 3:01 11:01
Negative ITA-6 4:07 11:01
Negative 17.ES 7:01 11:01
Negative 21.ES 10:01 11:01
Negative 12.ES 3:01 11:04
Negative 13.ES 4:01 11:04
Negative ITA-44 7:01 12:01 02:– 3:01
Negative 9.ES 3:01 13:01
Negative 20.ES 10:01 13:01
Negative ITA-8 11:04 13:01
Negative ITA-11 1:01 13:02
Negative ITA-1 11:03 13:02
Negative 1.ES 1:01 13:03
Negative 24.ES 11:03 13:03
Negative ITA-2 11:04 13:03
Negative 18.ES 7:01 13:05
Negative 15.ES 7:01 14:01
Negative 14.ES 4:02 15:01 03:– 6:02
Negative 16.ES 7:01 15:01 02:– 6:02
Table 2 Detailed HLA class II results including DRB1 alleles from
all patients and DQB1 from DRB1*15 positive patients
(Continued)
CIDP type ID DRB1* DRB1* DQB1* DQB1*
Negative 22.ES 10:01 15:01 05:– 6:02
Negative ITA-9 11:04 16:02
Negative 25.ES 11:04 15:01 03:– 6:02
Negative 27.ES 13:01 15:01 6:02 6:02
Negative 28.ES 11:01/04 16:01
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NF155+ patients had, at least, a brain MRI available and
none of them showed central demyelinating lesions. Al-
though DRB1*15 alleles have also been associated to other
autoimmune diseases, including the IgG4-mediated anti-
PLA2R membranous nephropathy [27], the association of
DRB1*15 with three different diseases (multiple sclerosis,
multifocal motor neuropathy, and anti-NF155+ CIDP) in
which myelinating cells (oligodendrocytes and Schwann
cells) are targeted by immune system may suggest conver-
gent pathophysiological mechanisms in which myelin anti-
gen presentation with DRB1*15 HLA class II is central.
Some reports suggest that Schwann cells express HLA-DR
in their surface, particularly in inflammatory neuropathies
[28], but whether DRB1*15 alleles are expressed more effi-
ciently in myelinating cells in comparison with other DRB1
alleles has never been studied.
Conclusions
DRB1*15 alleles strongly associate to anti-NF155+ CIDP
providing genetic evidence to support the idea that the
clinical, electrophysiological, pathological, and genetic
heterogeneity of CIDP disappears when the disease is
segregated according to highly specific biomarkers like
anti-NF155 antibodies.
Additional file
Additional file 1: This excel file is composed by five different tables.
Tables S1 and S2 display all peptides that the IEDB tool predicted to
bind to DRB1*15:01 and DRB1*15:02 alleles, respectively, ordered by
predicted binding strenght. Table S3. displays the 10 peptides binding
with highest scores to DRB1*15 alleles as calculated by the ProPred tool.
Table S4. displays all NF155 peptides ordered by their calculated
antigenicity according to the Kolaskar and Tongaonkar antigenicity scale.
Table S5. displays a summary of the findings relating the antigenicity
scale findings with HLA-peptide prediction results with both IEDB and
ProPred methods. (XLS 893 kb)
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